What is the 13F Pro Quality Score for ETON?

13F Pro ranks Eton Pharmaceuticals, Inc. (ETON) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ETON's current score at https://13fpro.ai/research/ETON (free sign-up required for the full ranking).

Which hedge funds own the most ETON stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ETON include Opaleye Management, EcoR1 Capital,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ETON as soon as new 13F filings post.

Where does 13F Pro source ETON data?

All Eton Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Eton Pharmaceuticals, Inc. files with the SEC under CIK 1710340. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ETON in?

Eton Pharmaceuticals, Inc. (ETON) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ETON research updated on 13F Pro?

ETON's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Eton Pharmaceuticals, Inc.(ETON)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1710340 ETON stock profile & AI dashboard →

13F Pro Quality Score

51.9/100

Rank #1,374 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.6/100

Profitability

36.4/100

Balance Sheet

24.1/100

Earnings Quality

30.0/100

Free Cash Flow

88.5/100

Institutional Flow

82.3/100

Revenue Scale

15.4/100

Dilution Risk

21.6/100

ETON Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Eton Pharmaceuticals, Inc. (ETON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ETON at 51.9/100 on a 32-signal composite quality model, placing it at rank #1,374 of 2,879 stocks — the top half of the AI-ranked universe. ETON scores in the top quartile across revenue growth (93.6), free cash flow (88.5), institutional flow (82.3). Areas of concern include revenue scale (15.4) and balance sheet strength (24.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Eton Pharmaceuticals, Inc. reports quarterly revenue of $24.3M, net income of $1.6M, free cash flow of $7.3M. Top institutional holders of ETON by reported 13-F value include Opaleye Management, EcoR1 Capital,, BlackRock,, based on the most recent SEC filings. ETON trades on the Nasdaq exchange and files with the SEC under CIK 1710340. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ETON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Eton Pharmaceuticals, Inc. directly from SEC EDGAR. Eton Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 43 and 56 since 2024, currently 51.9 — an improving long-term trajectory across 21 quarterly and live scoring snapshots.

✦

Fun facts about Eton Pharmaceuticals, Inc.

Quirks, history, and lore behind ETON — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in Illinois.
2
The Numbers
Annual revenue in the low tens of millions of dollars — this is a small but growing niche player, not a blockbuster pharma giant.
3
The History
Founded in 2013, it built its strategy around acquiring and developing FDA-approved drugs that treat rare or underserved medical conditions.
4
The Secret
Rather than hunting for brand-new molecules, this company focuses on reformulating or relaunching existing drugs — finding value where bigger players stopped looking.
5
The Lore
Its portfolio includes treatments for adrenal insufficiency and other rare endocrine and hospital-based conditions — tiny patient populations, but critical unmet needs.
6
The Giveaway
Named after a prestigious English boarding school, this Illinois pharma company trades under a four-letter ticker that's just its school-inspired name shortened to four letters.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$24.3M

Net Income

Q1 2026

$1.6M

Free Cash Flow

Q1 2026

$7.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+104.9% YoY

$80.0MFY 2025

FY22 $21.3MFY23 $31.6MFY24 $39.0MFY25 $80.0M

Net Income

-20.4% YoY

$-4.6MFY 2025

FY22 $-9.0MFY23 $-936.0KFY24 $-3.8MFY25 $-4.6M

Operating Income

+67.5% YoY

$-844.0KFY 2025

FY22 $-8.3MFY23 $-1.2MFY24 $-2.6MFY25 $-844.0K

Total Assets

+21.0% YoY

$92.1MFY 2025

FY22 $25.0MFY23 $31.7MFY24 $76.1MFY25 $92.1M

Total Debt

+32.0% YoY

$39.3MFY 2025

FY22 $6.4MFY23 $5.4MFY24 $29.8MFY25 $39.3M

Op. Cash Flow

+986.1% YoY

$10.5MFY 2025

FY22 $4.8MFY23 $6.8MFY24 $969.0KFY25 $10.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$80.0M +104.9%	$39.0M +23.3%	$31.6M +48.9%	$21.3M -2.7%	$21.8M +55879.5%	$39.0K
Net Income	$-4.6M -20.4%	$-3.8M -308.4%	$-936.0K +89.6%	$-9.0M -361.4%	$-2.0M +93.0%	$-28.0M
Operating Income	$-844.0K +67.5%	$-2.6M -117.9%	$-1.2M +85.6%	$-8.3M -452.5%	$-1.5M +94.5%	$-27.1M
Total Assets	$92.1M +21.0%	$76.1M +139.8%	$31.7M +26.8%	$25.0M -8.9%	$27.5M +4.4%	$26.3M
Total Debt	$39.3M +32.0%	$29.8M +454.1%	$5.4M -16.2%	$6.4M -3.9%	$6.7M +2.3%	$6.5M
Operating Cash Flow	$10.5M +986.1%	$969.0K -85.8%	$6.8M +41.4%	$4.8M +202.1%	$-4.7M +78.9%	$-22.3M

Get alerted when ETON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Eton Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ETON

Opaleye Management Inc.
$70.6M2,860,000 sh
EcoR1 Capital, LLC
$53.6M2,171,938 sh
BlackRock, Inc.
$42.4M1,717,286 sh
Nantahala Capital Management, LLC
$29.0M1,175,951 sh
VANGUARD CAPITAL MANAGEMENT LLC
$24.5M994,089 sh
GEODE CAPITAL MANAGEMENT, LLC
$14.3M577,666 sh
STATE STREET CORP
$13.1M530,215 sh
National Philanthropic Trust
$12.1M492,112 sh
MORGAN STANLEY
$11.8M477,957 sh
Westside Investment Management, Inc.
$11.5M467,915 sh

Fund	Value	Shares
Opaleye Management Inc.	$70.6M	2,860,000
EcoR1 Capital, LLC	$53.6M	2,171,938
BlackRock, Inc.	$42.4M	1,717,286
Nantahala Capital Management, LLC	$29.0M	1,175,951
VANGUARD CAPITAL MANAGEMENT LLC	$24.5M	994,089
GEODE CAPITAL MANAGEMENT, LLC	$14.3M	577,666
STATE STREET CORP	$13.1M	530,215
National Philanthropic Trust	$12.1M	492,112
MORGAN STANLEY	$11.8M	477,957
Westside Investment Management, Inc.	$11.5M	467,915

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ETON on your watchlist

Track score changes the day Eton Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ETON a good stock to buy?

13F Pro's AI-powered analysis of Eton Pharmaceuticals, Inc. (ETON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ETON are available on the ETON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ETON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ETON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Eton Pharmaceuticals, Inc.'s investment landscape.